Na Machị 16, 2025, Akeso kwupụtara na National Medical Products Administration (NMPA) enyela ikike maka ọgwụgwọ mbụ nke kansa nasopharyngeal relapse maọbụ metastatic metastatic (NPC) yana chemotherapy.
Penpulimab (PD-1 Monoclonal Antibody) bụ naanị ọgwụ mgbochi monoclonal PD-1 dị iche nke na-etinye ụdị IgG1 na Fc-nulldomain agbanweela, nke nwere ike ime ka arụmọrụ immunotherapy dịkwuo mma ma belata mmeghachi omume ọjọọ metụtara ahụ ike. A na-eji ya agwọ ọrịa ndị bụ isi dịka kansa akpa ume, lymphoma, kansa nasopharyngeal, kansa imeju, na kansa afọ, yana nchekwa na irè ka mma dịka egosiri na ọmụmụ ihe ahụike.
Nke a bụ ihe ngosi nke anọ akwadoro maka penpulimab. Na mgbakwunye na ihe ngosi NPC abụọ ahụ, a na-akwadokwa penpulimab maka ọgwụgwọ mbụ nke kansa akpa ume nke dị elu ma ọ bụ nke na-abụghị obere mkpụrụ ndụ (NSCLC) mgbe ejikọtara ya na kemoterapi, yana maka ọgwụgwọ otu onye na ndị nwere ọrịa lymphoma Hodgkin classical (cHL) nke na-alaghachi azụ ma ọ bụ nke na-adịghị anabata ọgwụgwọ bụ ndị natara ma ọ dịkarịa ala usoro abụọ nke kemoterapi sistemụ. Ọzọkwa, a na-enyocha ngwa ọgwụ ọhụrụ (sNDA) maka penpulimab yana anlotinib maka ọgwụgwọ mbụ nke kansa hepatocellular dị elu (HCC) ugbu a.
Na mbụ, a kwadoro penpulimab ka ọ bụrụ ọgwụgwọ nke atọ maka NPC dị elu. Site na nkwenye ọhụrụ a, penpulimab na-enye ugbu a mkpuchi ọgwụgwọ zuru oke n'ofe ọkwa niile nke NPC, na-enye ndị ọrịa nhọrọ ọgwụgwọ immunotherapy na-aga n'ihu site na ọgwụgwọ nke mbụ ruo nke atọ.
Na June 19, 2024, "Mgbaàmà Mgbanwe na Ọgwụgwọ Ezubere Iche" bipụtara nsonaazụ nke ọmụmụ nkebi nke abụọ gbasara ọgwụgwọ nke ọrịa kansa nasopharyngeal metastatic nke a gwọrọ na mbụ yana pembrolizumab.
Nnwale a nke otu aka, nke usoro nke abụọ emere n'ofe ụlọọgwụ 20 dị na China debara aha ndị ọrịa toro eto nwere kansa nasopharyngeal metastatic (NPC) bụ ndị dara usoro abụọ ma ọ bụ karịa nke chemotherapy sistemu gara aga. Ndị ọrịa natara 200-mg penpulimab n'ime akwara kwa izu abụọ (izu anọ kwa okirikiri) ruo mgbe ọrịa ahụ ga-aga n'ihu ma ọ bụ ihe ndị na-adịghị mma. Isi njedebe bụ ọnụego nzaghachi ebumnuche (ORR) kwa RECIST (ụdị 1.1), dịka kọmitii nyocha redio nọọrọ onwe ya si nyochaa. Isi njedebe nke abụọ gụnyere ndụ na-enweghị ọganihu (PFS) na ndụ zuru oke (OS). E debanyere aha otu narị ndị ọrịa iri atọ, a na-enyochakwa 125 nke ọma. Na ụbọchị njedebe data (Septemba 28, 2022), otu onye ọrịa nwetara nzaghachi zuru oke na ndị ọrịa 34 nwetara nzaghachi akụkụ. ORR bụ 28.0% (95% CI 20.3–36.7%). Azịza ahụ siri ike, yana 66.8% ka nọ na nzaghachi na ọnwa 9. Ndị ọrịa iri atọ na atọ (26.4%) ka nọ na ọgwụgwọ. Ndị ọrịa PFS na OS dị n'etiti dị ọnwa 3.6 (95% CI = ọnwa 1.9–7.3) na ọnwa 22.8 (95% CI = ọnwa 17.1 ka e ruteghị), n'otu n'otu. Ndị ọrịa iri (7.6%) nwere IRAE ọkwa nke atọ ma ọ bụ karịa. Penpulimab nwere ihe ndị na-egbochi etuto ahụ na ihe ndị na-egbu egbu a na-anabata nke ọma na ndị ọrịa NPC nke a na-agwọbeghị nke ukwuu, na-akwado mmepe ahụike ọzọ dị ka ọgwụgwọ nke atọ nke NPC nke a na-agwọbeghị.
Ugbu a, enwere ọtụtụ nnwale ahụike nke teknụzụ ọhụrụ na-egbochi kansa na China na-achọ ndị ọrịa. Maka ndụmọdụ gbasara ọgwụ na teknụzụ ọhụrụ, ị nwere ike ịkpọtụrụ Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region.
Nọmba ekwentị: 4008803716
Email：myimmnet@163.com
Oge ozi: Eprel-25-2025